{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2019-01-08&hansardHeading=Cannabis%3A+Medical+Treatments", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-date=2019-01-08&hansardHeading=Cannabis%3A+Medical+Treatments", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2019-01-08&_metadata=all&hansardHeading=Cannabis%3A+Medical+Treatments", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-date=2019-01-08&hansardHeading=Cannabis%3A+Medical+Treatments", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2019-01-08&hansardHeading=Cannabis%3A+Medical+Treatments", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?max-date=2019-01-08&hansardHeading=Cannabis%3A+Medical+Treatments", "items" : [{"_about" : "http://data.parliament.uk/resources/1037890", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037890/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "206442"}
        , {"_value" : "206443"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-16T15:13:41.753Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many NHS prescriptions have been issued for patients to use medical cannabis since 1 November 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "206441"}
    , {"_about" : "http://data.parliament.uk/resources/1037900", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037900/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "206441"}
        , {"_value" : "206443"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-16T15:13:41.817Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis have been dispensed at a pharmacy since 1 November 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "206442"}
    , {"_about" : "http://data.parliament.uk/resources/1037901", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037901/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department has made no estimate of future demand for medical cannabis over the next 12 months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-16", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : [{"_value" : "206441"}
        , {"_value" : "206442"}
        ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-16T15:13:41.847Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-08", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of (a) prescriptions of and (b) patients who will use medical cannabis in the next 12 months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "206443"}
    , {"_about" : "http://data.parliament.uk/resources/1037068", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1037068/answer", "answerText" : {"_value" : "<p>NHS England has set up systems to monitor the prescribing of cannabis-based products for medicinal use via the NHS Business Services Authority and NHS England Controlled Drugs Accountable Officers. We expect the first data to be available by the end of March 2019.<\/p><p> <\/p><p>The Department does not hold information on the number of patients denied access to prescriptions for medicinal cannabis.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2019-01-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-01-10T17:08:42.727Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-01-07", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of patients who have been (a) prescribed medicinal cannabis through the NHS and (b) denied a prescription for medicinal cannabis through the NHS since its use was legalised in November 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/308", "label" : {"_value" : "Biography information for Mr Jim Cunningham"}
      }
      , "tablingMemberConstituency" : {"_value" : "Coventry South"}
      , "tablingMemberPrinted" : [{"_value" : "Mr Jim Cunningham"}
      ], "uin" : "205815"}
    , {"_about" : "http://data.parliament.uk/resources/1005764", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1005764/answer", "answerText" : {"_value" : "<p>The Medical Director of NHS England, Professor Steve Powis, and the Chief Medical Officer, Professor Dame Sally Davies, have written to relevant clinicians to coincide with the coming into force of the rescheduling of cannabis-based medicinal products. The guidance in this letter, which signposts interim clinical advice commissioned from the British Paediatric Neurology Association and the Royal College of Physicians, is in line with normal clinical practice. The decision to prescribe cannabis-based products for medicinal use will be made on a case-by-case basis, based on clinical need and in-line with existing governance procedures for prescribing unlicensed medicines.<\/p><p> <\/p><p>The Department has commissioned the National Institute for Health and Care Excellence to produce clinical guidance by October 2019, which will update and replace the interim advice.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-15T12:47:21.367Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of NHS and medical professional body guidelines on the prescription of medicinal cannabis in ensuring the eligibility for prescription of patients for whom that treatment might be advantageous.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/478", "label" : {"_value" : "Biography information for Lord Field of Birkenhead"}
      }
      , "tablingMemberConstituency" : {"_value" : "Birkenhead"}
      , "tablingMemberPrinted" : [{"_value" : "Frank Field"}
      ], "uin" : "190361"}
    , {"_about" : "http://data.parliament.uk/resources/1003743", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1003743/answer", "answerText" : {"_value" : "<p>The Government has rescheduled cannabis-based products for medicinal use from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. Doctors on the specialist register of the General Medical Council may now prescribe these products where there might be potential benefit to individual patients. General practitioners will not be able to prescribe but the Government has commissioned the National Institute for Health and Care Excellence to produce guidance for all clinicians by October 2019.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-11-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-20T11:38:40.057Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-11-09", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to increase the (a) knowledge and (b) awareness among GPs of the benefits of medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"}
      }
      , "tablingMemberConstituency" : {"_value" : "Gower"}
      , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"}
      ], "uin" : "189815"}
    , {"_about" : "http://data.parliament.uk/resources/1002678", "AnsweringBody" : [{"_value" : "Home Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1002678/answer", "answerText" : {"_value" : "<p>The prescription of these products by doctors on the Specialist Register of the General Medical Council (GMC) and only where there is an unmet clinical need follows the principles used by the Interim Expert Panel on cannabis-based products for medicinal use. This approach was agreed by senior clinicians on the Expert Panel, Chaired by Dr Michael McBride, Chief Medical Officer for Northern Ireland. This approach was subsequently supported by the Advisory Council on the Misuse of Drugs (ACMD) in their advice to the Home Secretary on rescheduling cannabis. The ACMD advice has been published and is available at the following link:<\/p><p><a href=\"https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products\" target=\"_blank\">https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products<\/a><\/p><p>Any unlicensed medicines, including cannabis-based products for medicinal use, will be supplied under long-standing arrangements for the supply of what are known, in healthcare settings, as \u2018specials\u2019. This process is underpinned by the Human Medicines Act and, outside of clinical trials, only allows these unlicensed medicines to be prescribed where there is an unmet clinical need. This restriction is in place because unlicensed medicines have not been through the same quality, safety and efficacy tests as licenced medicines.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
        }
        , "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
        , "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
        , "dateOfAnswer" : {"_value" : "2018-11-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-12T17:05:51.537Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "1"}
      , "answeringDeptShortName" : {"_value" : "Home Office"}
      , "answeringDeptSortName" : {"_value" : "Home Office"}
      , "date" : {"_value" : "2018-11-06", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for the Home Department, if he will publish the advice used to inform his Department on the requirements that (a) the decision to prescribe medicinal cannabis products must be made by a specialist doctor and (b) medicinal cannabis products may only be prescribed when the patient has an unmet special clinical need that cannot be met by other treatments.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
      }
      , "tablingMemberConstituency" : {"_value" : "North Norfolk"}
      , "tablingMemberPrinted" : [{"_value" : "Norman Lamb"}
      ], "uin" : "188750"}
    , {"_about" : "http://data.parliament.uk/resources/1002107", "AnsweringBody" : [{"_value" : "Home Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1002107/answer", "answerText" : {"_value" : "<p>The Home Office leads the Government\u2019s policy and legislation on the misuse of drugs, including on the scheduling of substances controlled under the Misuse of Drugs Act 1971 and associated legislation. The Department of Health and Social Care has responsibility for the safe management and use of medicines in healthcare.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
        }
        , "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
        , "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
        , "dateOfAnswer" : {"_value" : "2018-11-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-11-15T17:58:05.597Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "1"}
      , "answeringDeptShortName" : {"_value" : "Home Office"}
      , "answeringDeptSortName" : {"_value" : "Home Office"}
      , "date" : {"_value" : "2018-11-05", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for the Home Department, whether his Department remains the ministerial lead for the medicinal use of cannabis-based products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4465", "label" : {"_value" : "Biography information for Ronnie Cowan"}
      }
      , "tablingMemberConstituency" : {"_value" : "Inverclyde"}
      , "tablingMemberPrinted" : [{"_value" : "Ronnie Cowan"}
      ], "uin" : "188186"}
    , {"_about" : "http://data.parliament.uk/resources/990352", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/990352/answer", "answerText" : {"_value" : "<p>NHS England expects that cannabis-based products for medicinal use should only be prescribed for indications where there is clear evidence of benefit, and in patients where there is a clinical need which cannot be met by a licensed medicine and, where established treatment options have been exhausted.<\/p><p> <\/p><p>The decision to prescribe these unlicensed medicines must be made by a specialist doctor \u2013 not a general practitioner. These doctors focus on one field of medicine such as neurology or paediatrics and are listed on the General Medical Council\u2019s specialist register. They must make decisions on prescribing cannabis-based products for medicinal use on a case by case basis, and only when the patient has an unmet special clinical need that cannot be met by licensed products. In addition, a specialist on the General Medical Council Register should only prescribe within their own area of practice, and the decision to prescribe should be agreed by the multidisciplinary team.<\/p><p> <\/p><p>NHS England, the British Paediatric Neurology Association and the Royal College of Physicians will provide clinical advice to doctors ahead of the law change. The National Institute for Health and Care Excellence has been commissioned to develop more detailed guidelines for clinicians in the longer term.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
        }
        , "answeringMemberConstituency" : {"_value" : "Winchester"}
        , "answeringMemberPrinted" : {"_value" : "Steve Brine"}
        , "dateOfAnswer" : {"_value" : "2018-10-23", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-23T16:43:24.827Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-10-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to allow patients to have access to NHS doctors willing to prescribe cannabis-based medicine in cases where their NHS doctor is unwilling to do so.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1400", "label" : {"_value" : "Biography information for Kevin Brennan"}
      }
      , "tablingMemberConstituency" : {"_value" : "Cardiff West"}
      , "tablingMemberPrinted" : [{"_value" : "Kevin Brennan"}
      ], "uin" : "181179"}
    , {"_about" : "http://data.parliament.uk/resources/988887", "AnsweringBody" : [{"_value" : "Home Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/988887/answer", "answerText" : {"_value" : "<p>From 1 November, certain cannabis-based products for medicinal use, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council (GMC). GPs will not be able to prescribe cannabis-based medicinal products for their patients.<\/p><p>There is no requirement for specialist doctors to notify the police or the Home Office when issuing prescription for these products. Controlled Drug Accountable Officers have a statutory responsibility to secure the safe management and use of controlled drugs. This includes a duty to monitor the prescribing, supply and administration (if applicable) of all controlled drugs and liaise with the police to investigate suspected diversion.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1561", "label" : {"_value" : "Biography information for Mr Nick Hurd"}
        }
        , "answeringMemberConstituency" : {"_value" : "Ruislip, Northwood and Pinner"}
        , "answeringMemberPrinted" : {"_value" : "Mr Nick Hurd"}
        , "dateOfAnswer" : {"_value" : "2018-10-24", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-10-24T15:40:57.027Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "1"}
      , "answeringDeptShortName" : {"_value" : "Home Office"}
      , "answeringDeptSortName" : {"_value" : "Home Office"}
      , "date" : {"_value" : "2018-10-16", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for the Home Department, whether GPs will be required to notify (a) the police and (b) the Home Office when making prescriptions for medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4491", "label" : {"_value" : "Biography information for Vicky Foxcroft"}
      }
      , "tablingMemberConstituency" : {"_value" : "Lewisham, Deptford"}
      , "tablingMemberPrinted" : [{"_value" : "Vicky Foxcroft"}
      ], "uin" : "180264"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&max-date=2019-01-08&hansardHeading=Cannabis%3A+Medical+Treatments", "page" : 0, "startIndex" : 1, "totalResults" : 44, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}